Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Michelle Simone Clement"'
Autor:
Stine Karlsen Oversoe, Michelle Simone Clement, Britta Weber, Henning Grønbæk, Stephen Jacques Hamilton-Dutoit, Boe Sandahl Sorensen, Jens Kelsen
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background and aims Studies suggest that mutations in the CTNNB1 gene are predictive of response to immunotherapy, an emerging therapy for advanced hepatocellular carcinoma (HCC). Analysis of circulating tumor DNA (ctDNA) offers the possibil
Externí odkaz:
https://doaj.org/article/d55854123f184e32a815ea076f23f8ec
Autor:
Kristine Raaby Gammelgaard, Johan Vad-Nielsen, Michelle Simone Clement, Simone Weiss, Tina Fuglsang Daugaard, Frederik Dagnæs-Hansen, Peter Meldgaard, Boe Sandahl Sorensen, Anders Lade Nielsen
Publikováno v:
Translational Oncology, Vol 12, Iss 3, Pp 432-440 (2019)
Non-small cell lung carcinoma patients with epidermal growth factor receptor (EGFR) mutations are offered EGFR tyrosine kinase inhibitors (TKI) as first line treatment, but 20–40% of these patients do not respond. High expression of alternative rec
Externí odkaz:
https://doaj.org/article/95de9a5034e840a880f923bc69715d00
Publikováno v:
Clement, M S, Ebert, E B F, Meldgaard, P & Sorensen, B S 2021, ' Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients ', Clinical Lung Cancer, vol. 22, no. 6, pp. e870-e877 . https://doi.org/10.1016/j.cllc.2021.05.002
Background: Intrinsic resistance is a major obstacle in treatment of non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR). We investigated co-occurring genetic alterations in circulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::587e62786eaf188ed8b5fdde6fafc70e
https://pure.au.dk/portal/da/publications/cooccurring-met-amplification-predicts-inferior-clinical-response-to-firstline-erlotinib-in-advanced-stage-egfrmutated-nsclc-patients(c53c8bf1-6c65-4a99-980e-796db99ec847).html
https://pure.au.dk/portal/da/publications/cooccurring-met-amplification-predicts-inferior-clinical-response-to-firstline-erlotinib-in-advanced-stage-egfrmutated-nsclc-patients(c53c8bf1-6c65-4a99-980e-796db99ec847).html
Autor:
Peter Meldgaard, Johan Vad-Nielsen, Simone Weiss, Anders Lade Nielsen, Kristine Raaby Gammelgaard, Tina Fuglsang Daugaard, Michelle Simone Clement, Frederik Dagnæs-Hansen, Boe Sandahl Sorensen
Publikováno v:
Translational Oncology, Vol 12, Iss 3, Pp 432-440 (2019)
Gammelgaard, K R, Vad-Nielsen, J, Clement, M S, Weiss, S, Daugaard, T F, Dagnæs-Hansen, F, Meldgaard, P, Sorensen, B S & Nielsen, A L 2019, ' Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC ', Translational Oncology, vol. 12, no. 3, pp. 432-440 . https://doi.org/10.1016/j.tranon.2018.11.017
Translational Oncology
Gammelgaard, K R, Vad-Nielsen, J, Clement, M S, Weiss, S, Daugaard, T F, Dagnæs-Hansen, F, Meldgaard, P, Sorensen, B S & Nielsen, A L 2019, ' Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC ', Translational Oncology, vol. 12, no. 3, pp. 432-440 . https://doi.org/10.1016/j.tranon.2018.11.017
Translational Oncology
Non-small cell lung carcinoma patients with epidermal growth factor receptor (EGFR) mutations are offered EGFR tyrosine kinase inhibitors (TKI) as first line treatment, but 20-40% of these patients do not respond. High expression of alternative recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bbcdb84fa976235759fe23349da9926
http://www.sciencedirect.com/science/article/pii/S1936523318304364
http://www.sciencedirect.com/science/article/pii/S1936523318304364
Autor:
Henning Grønbæk, Stephen Hamilton-Dutoit, Michelle Simone Clement, Stine Karlsen Oversoe, Britta Weber, Boe Sandahl Sorensen, Jens Kelsen
Publikováno v:
BMC Cancer
Oversoe, S K, Clement, M S, Weber, B, Grønbæk, H, Hamilton-Dutoit, S J, Sorensen, B S & Kelsen, J 2021, ' Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma ', BMC Cancer, vol. 21, no. 1, 376 . https://doi.org/10.1186/s12885-021-08103-0
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Oversoe, S K, Clement, M S, Weber, B, Grønbæk, H, Hamilton-Dutoit, S J, Sorensen, B S & Kelsen, J 2021, ' Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma ', BMC Cancer, vol. 21, no. 1, 376 . https://doi.org/10.1186/s12885-021-08103-0
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Background and aims Studies suggest that mutations in the CTNNB1 gene are predictive of response to immunotherapy, an emerging therapy for advanced hepatocellular carcinoma (HCC). Analysis of circulating tumor DNA (ctDNA) offers the possibility of se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f089cd53672980a86e57b42437499b7
http://europepmc.org/articles/PMC8028749
http://europepmc.org/articles/PMC8028749
TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma
Autor:
Stine Karlsen Oversoe, Britta Weber, Michael H Pedersen, Niels Kristian Aagaard, Stephen Hamilton-Dutoit, Michelle Simone Clement, Henning Grønbæk, Gerda Elisabeth Villadsen, Jens Kelsen, Boe Sandahl Sorensen
Publikováno v:
Oversoe, S K, Clement, M S, Pedersen, M H, Weber, B, Aagaard, N K, Villadsen, G E, Grønbæk, H, Hamilton-Dutoit, S J, Sorensen, B S & Kelsen, J 2020, ' TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma ', Scandinavian Journal of Gastroenterology, vol. 55, no. 12, pp. 1433-1440 . https://doi.org/10.1080/00365521.2020.1837928
BACKGROUND AND AIMS: Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations is an attractive biomarker. The telomerase reverse transcriptase (TERT) C228T promoter mutation is the most prevalent tumor-associated mutation in hepatocellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4beb4599beaea8c53619cd5620e1808b
https://pubmed.ncbi.nlm.nih.gov/33103505
https://pubmed.ncbi.nlm.nih.gov/33103505
Autor:
Stine Karlsen Oversoe, Michelle Simone Clement, Britta Weber, Henning Grønbæk, Stephen Jacques Hamilton-Dutoit, Boe Sandahl Sorensen, Jens Kelsen
Background and aims: Studies suggest that mutations in the CTNNB1 gene are predictive of response to immunotherapy, an emerging therapy for advanced hepatocellular carcinoma (HCC). Analysis of circulating tumor DNA (ctDNA) offers the possibility of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d78cebf9625c709b58f507985fd521a
https://doi.org/10.21203/rs.3.rs-88929/v1
https://doi.org/10.21203/rs.3.rs-88929/v1
Autor:
Kristine Raaby Gammelgaard, Boe Sandahl Sorensen, Anders Lade Nielsen, Michelle Simone Clement
Publikováno v:
Clement, M S, Gammelgaard, K R, Nielsen, A L & Sorensen, B S 2020, ' Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells ', Translational Lung Cancer Research, vol. 9, no. 5, pp. 1904-1914 . https://doi.org/10.21037/tlcr-20-522
Transl Lung Cancer Res
Transl Lung Cancer Res
Background: Tyrosine kinase inhibitor (TKI) resistance is a major obstacle in treatment of non-small cell lung cancer (NSCLC). MET amplification drives resistance to EGFR-TKIs in 5-20% of initially sensitive EGFR-mutated NSCLC patients, and combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad55d286339c7f5f7db5bad6db75d8e8
https://pure.au.dk/ws/files/220256120/tlcr_09_05_1904.pdf
https://pure.au.dk/ws/files/220256120/tlcr_09_05_1904.pdf
Publikováno v:
Molecular pathology and funct. genomics.
Currently there are five EGFR tyrosine kinase inhibitors (TKIs) available for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). However drug resistance is inevitable for virtually all patients and disease progression occurs within 1 t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ed25153b455cb1a8deefcbeadb1b351
https://doi.org/10.1183/13993003.congress-2020.330
https://doi.org/10.1183/13993003.congress-2020.330
Autor:
Boe Sandahl Sorensen, Stephen P. Finn, A. Tranberg Madsen, Kathy Gately, Sinead Cuffe, Michelle Simone Clement
Publikováno v:
Journal of Thoracic Oncology. 16:S561-S562
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e10c5461c17ebedcb8d9e95d03b3e07
https://doi.org/10.1016/j.jtho.2021.01.1009
https://doi.org/10.1016/j.jtho.2021.01.1009